RxDoctor Payments Data

Ana Conde Rosa, MD

Infectious Disease · Melbourne, FLNPI 1972674687

Payments from drug & device makers

$7,664in general payments, 2019–2025

Across 350 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$3K
  • Theratechnologies Inc.$631
  • Merck$562
  • Johnson & Johnson$321
  • AbbVie$236
  • plus $322 from 6 others

What the payments were for

  • Food & beverage$7,55999%
  • Education$1051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,664 in reported general payments places this provider in the 75th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$231,473
Medicare patients
609
Services billed
3,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala406$1,550,478
JulucaDolutegravir/Rilpivirine112$360,396
RukobiaFostemsavir Tromethamine39$348,345
TrogarzoIbalizumab-Uiyk26$340,463
GenvoyaElviteg/Cob/Emtri/Tenof Alafen78$274,636
TivicayDolutegravir Sodium94$258,474
OdefseyEmtricitab/Rilpiviri/Tenof Ala72$256,509
DovatoDolutegravir Sodium/Lamivudine83$237,516
DescovyEmtricitabine/Tenofov Alafenam98$201,391
CabenuvaCabotegravir/Rilpivirine30$198,545
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf41$185,148
TriumeqAbacavir/Dolutegravir/Lamivudi44$158,065
Egrifta SvTesamorelin Acetate14$98,377
PrezcobixDarunavir/Cobicistat37$88,101
CompleraEmtricita/Rilpivirine/Tenof Df12$43,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$2,899$2,026,505582 claims
Viiv Healthcare CompanyJuluca, Rukobia, Tivicay, Dovato, Cabenuva$2,694$1,561,341402 claims
Theratechnologies Inc.Trogarzo, Egrifta Sv$631$438,84040 claims
Janssen Products, LPSymtuza$30$185,14841 claims
Johnson & JohnsonPrezcobix, Complera$321$131,80649 claims
MerckIsentress, Lagevrio (Eua)$562$37,20124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →